aitios® platform (AI-powered liquid biopsy)

	Next higher product group	liquid biopsy
	Status	2024-10-01 development existent
	Organisation	Aitiologic GmbH
	Organisation 2	Siemens Healthineers AG (Frankfurt: SHL)
	Group	Siemens (Group)

Aitiologic GmbH. (10/1/24). "Press Release: Aitiologic Emerges from Stealth Mode with over €2.5M in Funding to Advance AI-powered Liquid Biopsy Platform for Early Disease Detection". Vienna.

Aitiologic, a precision diagnostics start-up, today announced its emergence from stealth mode, unveiling plans to develop its AI-powered aitios® platform for early disease detection and personalized medicine. The company has secured over €2.5M in total funding to date, including non-dilutive grants from the Austrian Promotional Bank (aws) and the Austrian Research Promotion Agency (FFG).

Aitiologic's patented technology, initially developed by one of the founders at Siemens Healthineers, analyzes circulating cell-free DNA (cfDNA) to pinpoint both the underlying cause as well as location of disease through a simple blood test. By tracing molecular alterations back to their tissue-of-origin, the company’s unique liquid biopsy approach, which combines genetic and epigenetic cfDNA testing with the aitios® platform for cloud-based interpretation, is set to significantly enhance non-invasive prenatal and oncology testing.

Established in June 2023 by a team of seasoned biotech entrepreneurs, Aitiologic has recently obtained an exclusive intellectual property license from Siemens Healthineers, with the goal of developing and commercializing AI-powered liquid biopsy solutions capable of decoding molecular health from a routine blood draw.

"Aitiologic has quietly initiated the development of something transformative," said Dr. Andreas Posch, Founder & CEO of Aitiologic. "Backed by a strong investor consortium led by PUSH VC and LANA Ventures, as well as funding from aws and FFG, we are well-positioned to add tissue-of-origin resolution to liquid biopsy testing. With promising proof-of-principle data for our aitios® platform, we are now working towards demonstrating feasibility in patient samples."

Anticipating key R&D milestones in cfDNA assay development and native sample testing, the company is preparing for growth to accelerate its development, analytical validation, and clinical efforts through 2025.

About Aitiologic

Aitiologic is a precision diagnostics company specializing in AI-powered liquid biopsy for early disease detection and personalized medicine. Building on patented technology licensed from Siemens Healthineers, the company develops the aitios® platform to decode molecular health from a simple blood test by tracing genetic and epigenetic alterations in circulating cell-free DNA (cfDNA) back to their tissue-of-origin. The company is headquartered in Vienna, Austria.

aitiologic GmbH is supported by the Austrian BMAW/BMK Seed - Deep Tech program coordinated by aws.

aitiologic GmbH
Karl-Farkas-Gasse 18
1030 Vienna
Austria

Record changed: 2024-10-06

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for liquid biopsy

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)